While targeted therapies have revolutionised precision medicine for NSCLC, resistance to first‐ and second‐generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) typically emerges within 9–14 months, often due to the EGFRT790M mutation.1, 2, 3, 4. Here, EGFR is linked to non-small cell lung carcinoma.